What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: A pooled analysis of 4 randomized placebo-controlled trials of duloxetine

Journal of Rheumatology

Volumn 36, Issue 11, 2009, Pages 2517-2522

  Hudson, James I ^a   Arnold, Lesley M ^b   Bradley, Laurence A ^c   Choy, Ernest H S ^d   Mease, Philip J ^e   Wang, Fujun ^f   Ahl, Jonna ^f   Wohlreich, Madelaine M ^f  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SWEDISH MEDICAL CENTER   (United States)

^f Lilly USA   (United States)

Author keywords

Fatigue; Fibromyalgia; Functioning; Pain; Predictors of improvement

Indexed keywords

DULOXETINE; PLACEBO;

ANALGESIA; ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DOUBLE BLIND PROCEDURE; EMOTION; FATIGUE; FIBROMYALGIA; HUMAN; MULTICENTER STUDY; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP; SOCIAL STATUS;

ANTIDEPRESSIVE AGENTS; DOUBLE-BLIND METHOD; FIBROMYALGIA; HUMANS; MULTICENTER STUDIES AS TOPIC; PAIN; PAIN MEASUREMENT; PLACEBOS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 70450191664     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090139     Document Type: Article

References (24)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172
2. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363-367
3. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993;20:475-479 (Pubitemid 23102471)
4. Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-2277
5. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patients Delphi exercises. Arthritis Rheum 2008;59:952-960 (Pubitemid 351990991)
6. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication Adm 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976.
7. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984 (Pubitemid 39209537)
8. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DL, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
9. Russell IJ, Mease P, Smith T, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial. Pain 2008;136:432-444
10. Chappell A, Bradley L, Wiltse C, Detke M, D'Souza D, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008;1:91-102.
11. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138
12. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-733
13. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
14. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11 Suppl:89-95.
15. Fischer AA. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 1986;67:836-838
16. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-597 (Pubitemid 26382973)
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
18. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325
19. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
20. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc; 1977.
21. Maier W, Philipp M. Comparative analysis of observer depression scales. Acta Psychiatr Scand 1985;72:239-245 (Pubitemid 16257029)
22. Capuron L, Welberg L, Heim C, Wagner D, Solomon L, Papanicolaou DA, et al. Cognitive dysfunction relates to subjective report of mental fatigue in patients with chronic fatigue syndrome. Neuropsychopharmacology 2006;31:1777-1784 (Pubitemid 44106709)
23. Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-120
24. Carville SF, Choy EH. Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol 2008;35:2094-2105